Ningbo-based API and CDMO manufacturer exporting active pharmaceutical ingredients to generic drugmakers abroad.
Ningbo-based API and CDMO manufacturer exporting active pharmaceutical ingredients to generic drugmakers abroad.
In one line: A small Chinese API/CDMO exporter.
Moat: none (scale). Commodity API/CDMO producer competing mainly on cost and regulatory filings.
Headquarters: Ningbo, China · Employees: 2,370
Size Ningbo Menovo Pharmaceutical (603538.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $945M, the 2259th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.98 on 18 Nov 2026.
Performance Over six months the shares fell 47.7%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 18.6% over the last twelve months (peer median -4.4%); the operating margin is 8.8% (peer median 12.2%).
Valuation It trades at 42.3× forward earnings against a peer median of 22.9× (3rd most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.2 points below its cost of capital (5.0% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.83B | CN¥1.50B | CN¥1.37B | CN¥1.21B | CN¥1.45B |
| Revenue growth | — | +10% | +13% | -16% | — |
| Gross profit | CN¥607M | CN¥489M | CN¥408M | CN¥334M | CN¥533M |
| EBITDA | n/a | CN¥278M | CN¥221M | CN¥146M | CN¥313M |
| Net income | CN¥110M | CN¥102M | CN¥66.8M | CN¥11.6M | CN¥339M |
| Free cash flow | CN¥76.4M | CN¥60.3M | -CN¥77.4M | -CN¥202M | -CN¥288M |
| Capital expenditure | CN¥149M | CN¥112M | CN¥179M | CN¥220M | CN¥572M |
| Total debt | CN¥1.08B | CN¥1.76B | CN¥1.65B | CN¥1.52B | CN¥1.43B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ningbo Menovo Pharmaceutical 603538.SS | $945M | -48% | +19% | 9% | 42.3× | 11.6% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603538.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.5% | -8.3% | 7th lowest of 21 |
| 6-month return | -47.7% | -18.4% | 2nd lowest of 21 |
| Distance from 52-week high | -62.2% | -44.2% | 5th lowest of 21 |
| Revenue growth (TTM) | +18.6% | -4.4% | 5th highest of 18 |
| Operating margin | 8.8% | 12.2% | 9th lowest of 18 |
| Forward P/E | 42.3× | 22.9× | 3rd most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 11.6% | 7.1% | 3rd most demanding of 11 |
| Growth delivered (Del g) | +4.9% | +8.5% | 5th lowest of 11 |
| Hurdle (Req g minus delivered) | +6.7 pp | -0.5 pp | 5th most demanding of 11 |
| ROIC minus cost of capital | -0.2 pp | -2.0 pp | 6th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | n/a | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 50.2× | -10.2% | +18.1% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 22.9× | 9.1% | +13.4% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 9.8× | -3.7% | +13.8% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |